Vor Biopharma (NASDAQ:VOR) Coverage Initiated at Wells Fargo & Company

Research analysts at Wells Fargo & Company assumed coverage on shares of Vor Biopharma (NASDAQ:VOR) in a research note issued on Thursday, Marketbeat reports. The firm set an “overweight” rating and a $30.00 price target on the stock. Wells Fargo & Company‘s price target indicates a potential upside of 149.17% from the company’s previous close.

Other equities research analysts have also recently issued reports about the company. JPMorgan Chase & Co. dropped their target price on Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Citigroup started coverage on Vor Biopharma in a research report on Friday, January 9th. They set a “buy” rating and a $50.00 price target on the stock. TD Cowen started coverage on Vor Biopharma in a report on Wednesday, December 17th. They issued a “buy” rating on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. Finally, Wedbush began coverage on Vor Biopharma in a research note on Tuesday, November 25th. They set a “neutral” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $49.88.

Vor Biopharma Stock Performance

VOR stock opened at $12.04 on Thursday. Vor Biopharma has a one year low of $2.62 and a one year high of $65.80. The firm’s fifty day moving average is $14.33 and its 200 day moving average is $19.20. The firm has a market cap of $125.34 million, a PE ratio of -0.03 and a beta of 1.99.

Institutional Trading of Vor Biopharma

Institutional investors have recently made changes to their positions in the company. RA Capital Management L.P. increased its position in shares of Vor Biopharma by 172.7% during the fourth quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after purchasing an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. lifted its holdings in Vor Biopharma by 852.8% in the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock valued at $47,315,000 after purchasing an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in Vor Biopharma during the 4th quarter worth $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in Vor Biopharma during the 4th quarter worth $22,890,000. Finally, NEXTBio Capital Management LP purchased a new stake in shares of Vor Biopharma during the fourth quarter worth $13,080,000. 97.29% of the stock is owned by institutional investors and hedge funds.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).